Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating substance abuse disorders

A substance abuse, composition technology, applied in the direction of drug combination, pharmaceutical formulation, drug delivery, etc., can solve problems such as abuse, adrenal insufficiency, limited applicability, etc.

Inactive Publication Date: 2018-11-09
EMBERA NEUROTHERAPEUTICS
View PDF13 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, both classes of drugs have potential side effects that can limit the applicability of the drugs in the treatment of cocaine addiction
For example, benzodiazepines are generally not recommended as a treatment option for cocaine dependence because of the abuse potential of these drugs (Chouinard, 2004; Lilja et al., 2001; O'Brien, 2005), raising concerns about their use. Concerns about possible secondary dependency (Wesson and Smith 1985)
Corticosterone synthesis inhibitors have the potential to produce especially adrenal insufficiency, which can also limit the utility of these drugs in particular

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating substance abuse disorders
  • Compositions and methods for treating substance abuse disorders
  • Compositions and methods for treating substance abuse disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0124] Effect of Low-Dose Combination Drug Therapy on Cocaine Self-Administration in Rats: The study described here examined combination drug therapy for the treatment of addiction (and more specifically, cocaine abuse) consistent with that described herein. Using this approach, two compounds that are thought to use different mechanisms of action to ultimately have similar effects on the body's response to a stressor are administered together at doses that are either ineffective or much less effective individually. Adult male Wistar rats were trained under multiple alternating cocaine and food self-administration regimens. This regimen consisted of alternating periods of cocaine access and food reinforcement. In some cases, as described further below, three doses of cocaine (0.125, 0.25 or 0.50 mg / kg per infusion) were tested. During the same training session, rats were also periodically trained with saline replacement (cocaine withdrawal) and food withdrawal.

[0125]These ...

Embodiment 2

[0154] This study was designed to assess the safety and pharmacokinetics of the combination of metyrapone (MET) and oxazepam (OX) in humans. The MET / OX combination (referred to herein as EMB-001) administered in this experiment was metyrapone (MET), a cortisol synthesis inhibitor, and oxazepam (OX), a benzodiazepine Miscellaneous Zhuo) combination. MET is FDA-approved for one-day use only as a test of pituitary function, and OX is approved for short- and long-term treatment of various anxiety disorders. Neither drug is currently approved to treat addiction or substance use disorders. In previous animal studies, EMB-001 reduced cocaine and nicotine self-administration and attenuated cocaine and methamphetamine cue reactivity in rats. In human studies of cocaine-dependent subjects, EMB-001 significantly reduced cocaine use.

[0155] method: This is a single and multiple ascending dose study. Healthy volunteers aged 18-65 years who smoked received a single AM ​​dose on day ...

Embodiment 3

[0159] Table 1

[0160]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention is directed to compositions and methods for treating substance abuse disorders and addiction. In particular, this invention is directed to combinations of low doses of a Cortisol synthesis inhibitor, such as metyrapone, in combination with low doses of a benzodiazepine, such as oxazepam. The compositions and methods of the invention include pharmaceutical compositions and methods that are safe and efficacious for treating animals and humans.

Description

[0001] Federally Funded Research [0002] This invention was made with government support under US Public Health Grant 1R01DA030932-01 awarded by the National Institute on Drug Abuse. technical field [0003] The present invention relates to methods for the treatment of various conditions and disorders, including neuropsychiatric disorders such as addiction, anxiety, depression, schizophrenia, and related conditions (such as insomnia), and more generally to the preparation and use of and methods of drug preparation in different tissues within the endocrine system. Background technique [0004] While scientists have been studying the neurobiology of psychomotor stimulant reward for decades, there are still no FDA-approved treatments for cocaine or methamphetamine abuse. Previous laboratory studies have focused on the relationship between stress, subsequent activation of the hypothalamic-pituitary-adrenal (HPA) axis, and reinforcement with psychomotor stimulants for nearly 30...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/5513A61K31/00A61K31/444
CPCA61K31/444A61K31/5513A61P25/30A61P25/36A61K2300/00A61K9/0053
Inventor 迈克尔·代特克卡罗尔·格洛夫朱莉·斯特劳布
Owner EMBERA NEUROTHERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com